The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
about
Unprecedented therapeutic potential with a combination of A2A/NR2B receptor antagonists as observed in the 6-OHDA lesioned rat model of Parkinson's diseasePharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signalingTreatment of Parkinson's disease: what's in the non-dopaminergic pipeline?New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors.Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.Levodopa-induced dyskinesias in Parkinson's disease: emerging treatmentsTherapeutic potential of targeting glutamate receptors in Parkinson's disease.Metaplasticity in human cortex.Basal ganglia dysfunction in complex regional pain syndrome - A valid hypothesis?Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias.Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease.Abnormal bidirectional plasticity-like effects in Parkinson's disease.The Kinase Fyn As a Novel Intermediate in L-DOPA-Induced Dyskinesia in Parkinson's Disease.
P2860
Q28542729-72C19F75-063E-4340-8271-5A6F01531536Q33428476-6C18140F-813D-4BC6-ACCC-AF195E3A0CCAQ37506507-256EAD47-6B21-4ED4-8C44-7CF7E305C726Q37974709-F7D988E7-FE07-406B-AFB7-76A2EB4A6A20Q38056852-4F1BD6F0-D602-426B-A940-EDC61C3CB52DQ38156760-B8BAE1B4-56AD-400B-B73F-807A80ED06A0Q38190016-FBE1CC06-39CE-4589-AB5C-88CA6A4815F8Q38195271-B4884713-B635-4CE4-B016-0D68C6667B29Q38996750-D68A03AE-B7F7-4A9E-8607-363DCDFA274EQ39324877-E69593B5-02C4-4D70-B7CE-29DAE9B0CA93Q40053132-AA4081B1-0DD0-439D-8733-08F046F5089EQ46987576-77541690-E392-4EB1-B129-05DF24B672EEQ48829642-D72981C1-B848-4162-9FB4-D91CEC014ADCQ53096926-22A65B0B-280C-40A4-8ECE-961D2C33243C
P2860
The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
description
2004 nî lūn-bûn
@nan
2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
The NR2B-selective NMDA recept ...... model of Parkinson's disease.
@ast
The NR2B-selective NMDA recept ...... model of Parkinson's disease.
@en
The NR2B-selective NMDA recept ...... model of Parkinson's disease.
@nl
type
label
The NR2B-selective NMDA recept ...... model of Parkinson's disease.
@ast
The NR2B-selective NMDA recept ...... model of Parkinson's disease.
@en
The NR2B-selective NMDA recept ...... model of Parkinson's disease.
@nl
prefLabel
The NR2B-selective NMDA recept ...... model of Parkinson's disease.
@ast
The NR2B-selective NMDA recept ...... model of Parkinson's disease.
@en
The NR2B-selective NMDA recept ...... model of Parkinson's disease.
@nl
P2093
P1476
The NR2B-selective NMDA recept ...... t model of Parkinson's disease
@en
P2093
Crossman AR
Ravenscroft P
P304
P356
10.1016/J.EXPNEUROL.2004.05.004
P407
P577
2004-08-01T00:00:00Z